Page last updated: 2024-11-12

succinyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

succinyladenosine: found in body fluids of children with severe psychomotor delay & autism; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

succinyladenosine : An aspartic acid derivative that is L-aspartic acid in which one of the amine hydrogens is substituted by a 9-beta-D-ribofuranosyl-9H-purin-6-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID20849086
CHEBI ID71169
SCHEMBL ID23780815
MeSH IDM0128124

Synonyms (28)

Synonym
succinyladenosine
l-aspartic acid, n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-
(s)-n-(1,2-dicarboxyethyl)-adenosine
6-(1,2-dicarboxyethylamino)-9-beta-d-ribofuranosylpurine
CHEBI:71169
(2s)-2-({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-9h-purin-6-yl}amino)butanedioic acid
succinoadenosine
n-9-ribofuranosyl-9h-purin-6-yl-aspartic acid
n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-l-aspartic acid
(2s)-2-({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-6-yl}amino)butanedioic acid
n-(9-beta-delta-ribofuranosyl-9h-purin-6-yl)-l-aspartic acid
6-(1,2-dicarboxyethylamino)-9-beta-delta-ribofuranosylpurine
6-(1,2-dicarboxyethylamino)-9-b-d-ribofuranosylpurine
n-(9-b-d-ribofuranosyl-9h-purin-6-yl)-l-aspartic acid
n-(9-beta-delta-ribofuranosyl-9h-purin-6-yl)-l-aspartate
n-9-ribofuranosyl-9h-purin-6-yl-aspartate
n-(9-b-d-ribofuranosyl-9h-purin-6-yl)-l-aspartate
Q27139416
MS-26287
CS-0059510
HY-113284
SCHEMBL23780815
AKOS040756152
(2s)-2-({9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl}amino)butanedioic acid
n6-succinyloadenosine
adenosine, n-(1,2-dicarboxyethyl)-, (s)-
aspartic acid, n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-, l-
FZN9Z367G5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
adenosinesAny purine ribonucleoside that is a derivative of adenosine.
amino dicarboxylic acid
L-aspartic acid derivativeA proteinogenic amino acid derivative resulting from reaction of L-aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of L-aspartic acid by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Purine metabolism1336
Purine metabolism and related disorders2353

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (15.38)18.7374
1990's7 (26.92)18.2507
2000's7 (26.92)29.6817
2010's8 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies11 (40.74%)4.05%
Observational0 (0.00%)0.25%
Other16 (59.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]